Membranous nephropathy
Conditions
Interventions
Supportive treatment group:None
Glucocorticoid + cyclophosphamide group:None
Glucocorticoid + calcineurin inhibitor (CNI) group:None
The rituximab group:None
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with membranous nephropathy (MN) diagnosed by renal biopsy in the Department of Nephrology, West China Hospital, Sichuan University from October 1, 2024 were enrolled. 2. Over 18 years old, no gender, race, etc.; 3. Patients with regular follow-up, i.e., at least every 3 months for 1 year after diagnosis until completion of 1 year of follow-up (prospective cohort). Demographic, clinical, and laboratory data will be collected at baseline, and relevant laboratory data will be collected every 3-6 months thereafter until study completion.
Exclusion criteria
Exclusion criteria: 1. Patients with membranous nephropathy due to secondary causes, including: known infection with hepatitis B or C virus or HIV; known malignant disease; positive double-stranded DNA antibody; currently treated with penicillamine, non-steroidal anti-inflammatory drugs, cytotoxic drugs or cyclosporine; treated with corticosteroids for more than 3 months in the previous two years; pregnant or contraceptive; or previous adverse reactions to prednisolone, methylprednisolone, chlorambucil or cyclosporine; 2. Patients who cannot be followed regularly.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Creatinine;Urine protein creatinine ratio;24-hour urinary protein quantity;The eGFR;Urinalysis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Urea;Uric Acid;ENA antibody profile;Blood routine examination;Complement factor 3;Complement factor 4;PLA2R; | — |
Countries
China
Contacts
Public ContactQin Wei
West China Hospital of Sichuan University
Outcome results
None listed